Information  X 
Enter a valid email address

Consort Medical Plc (CSRT)

  Print      Mail a friend       Annual reports

Monday 01 April, 2019

Consort Medical Plc

Total Voting Rights

RNS Number : 5122U
Consort Medical PLC
01 April 2019


Registered Number 406711

Consort Medical plc (the "Company")

Total Voting Rights

The Company hereby notifies the market of the following disclosure with respect to the share capital and voting rights of the Company: 

As at 31 March 2019, the capital of the Company consists of 49,364,234 ordinary shares of 10 pence each with voting rights. The Company does not hold any shares in Treasury at the date of this disclosure.

Therefore, the total number of voting rights in the Company is 49,364,234. 





Consort Medical plc

Michelle Palmer                                                                                              01442 867920


Consort Medical plc is a leading one-stop developer and manufacturer of drugs and premium drug delivery devices. We partner with pharmaceutical businesses in providing innovative life improving treatments to patients across the world through two integrated activities:

The design, development and manufacture of high performance medical devices for inhaled, injectable, nasal and ocular drug delivery, as well as point of care diagnostics products.

The development, formulation and manufacture of active pharmaceutical ingredients (APIs) and finished dose drugs to the highest quality standards.

We employ over 2,000 people globally and are committed to investing in patient, clinician and customer driven innovation to create new treatments.

Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE:CSRT) and is organised in two divisions: Bespak and Aesica.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t